Best time to take lorlatinib

Lorlatinib is an oral, third-generation ALK inhibitor, mainly used to treat ALK-positive or ROS1-positive advanced non-small cell lung cancer (NSCLC). The correct time and method of taking the drug are crucial to the effectiveness of the drug and the management of side effects.

Larlatinib is usually recommended to be taken once a day at a fixed time. The taking time can be chosen according to the patient's daily habits, such as morning or evening, but it needs to be consistent to ensure stable drug concentration in the body, thereby enhancing efficacy and reducing adverse reactions.

Although the taking time of lorlatinib is not affected by food, in order to avoid gastrointestinal discomfort, it is recommended that patients take it 30 minutes to 1 hour after a meal, and take it with an appropriate amount of warm water. This can reduce the irritation of the medicine to the stomach, and at the same time help develop good medication habits and prevent missed doses.

If the patient forgets to take the medicine, he should take it as soon as possible; but if the next dose is close (less than4 hours), he should skip the missed dose and take the next medicine directly at the original time. Do not take a double dose to avoid overdose and increased side effects.

For elderly patients or patients with impaired liver and kidney function, the medication time or dosage needs to be adjusted according to the doctor's recommendations. If patients experience significant adverse reactions (such as hyperlipidemia, peripheral neuropathy, etc.), they should communicate with their doctor in a timely manner. The medication time or regimen may need to be changed.

The best time to take lorlatinib is at a fixed time every day, and the effect is better when taken after meals. Maintaining regularity helps medications maximize their therapeutic effectiveness and reduces the risk of drug resistance. Patients should pay close attention to their body's reactions during medication and maintain communication with their doctors.

xa0

Reference materials

1.Pfizer official website:

https://www.pfizer.com

2.UpToDate - Lorlatinib overview and dosing:

https://www.uptodate.com/contents/lorlatinib-for-alk-positive-non-small-cell-lung-cancer